Cargando…
Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea
BACKGROUND: Although endocrine therapy is an effective treatment for breast cancer, its antiestrogen effects are associated with increased risks of cardiovascular diseases and type 2 diabetes. This study aimed to investigate the association between endocrine therapy and the risk of cardiovascular di...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673673/ https://www.ncbi.nlm.nih.gov/pubmed/36250658 http://dx.doi.org/10.1161/JAHA.122.026743 |
_version_ | 1784832994708553728 |
---|---|
author | Kim, Ji‐Eun Choi, Jaesung Park, JooYong Han, Wonshik Kang, Daehee Choi, Ji‐Yeob |
author_facet | Kim, Ji‐Eun Choi, Jaesung Park, JooYong Han, Wonshik Kang, Daehee Choi, Ji‐Yeob |
author_sort | Kim, Ji‐Eun |
collection | PubMed |
description | BACKGROUND: Although endocrine therapy is an effective treatment for breast cancer, its antiestrogen effects are associated with increased risks of cardiovascular diseases and type 2 diabetes. This study aimed to investigate the association between endocrine therapy and the risk of cardiovascular diseases and type 2 diabetes among breast cancer survivors in Korea, in consideration of various age groups. METHODS AND RESULTS: In the National Health Insurance Service database of Korea, a total of 133 171 patients with breast cancer aged ≥20 years were included in the current study. Endocrine therapy was treated as time‐varying exposure, and patients were categorized as nonusers, selective estrogen receptor modulator users, aromatase inhibitor users, and both users. Time‐dependent Cox regression models were used to estimate hazard ratios (HRs) and 95% CIs. Age at diagnosis, socioeconomic status, histological type, other treatments, and comorbidities were adjusted in the model. Compared with nonusers, selective estrogen receptor modulator users were associated with higher risks of stroke (HR, 1.20 [95% CI, 1.04–1.40]) and venous thromboembolism (HR, 1.47 [95% CI, 1.13–1.90]), whereas aromatase inhibitor users were associated with a higher risk of coronary heart disease (HR, 1.22 [95% CI, 1.06–1.41]). The risk of type 2 diabetes was associated with selective estrogen receptor modulator users (HR, 1.13 [95% CI, 1.05–1.21]), aromatase inhibitor users (HR, 1.14 [95% CI, 1.05–1.23]), and both users (HR, 1.24 [95% CI, 1.10–1.39]). In particular, the risk of a composite of cardiovascular diseases was higher in younger or premenopausal patients. CONCLUSIONS: In breast cancer survivors in Korea, endocrine therapy is associated with a higher risk of cardiovascular diseases and type 2 diabetes. Monitoring of cancer comorbidities after endocrine therapy is needed in younger and older patients. |
format | Online Article Text |
id | pubmed-9673673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96736732022-11-21 Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea Kim, Ji‐Eun Choi, Jaesung Park, JooYong Han, Wonshik Kang, Daehee Choi, Ji‐Yeob J Am Heart Assoc Original Research BACKGROUND: Although endocrine therapy is an effective treatment for breast cancer, its antiestrogen effects are associated with increased risks of cardiovascular diseases and type 2 diabetes. This study aimed to investigate the association between endocrine therapy and the risk of cardiovascular diseases and type 2 diabetes among breast cancer survivors in Korea, in consideration of various age groups. METHODS AND RESULTS: In the National Health Insurance Service database of Korea, a total of 133 171 patients with breast cancer aged ≥20 years were included in the current study. Endocrine therapy was treated as time‐varying exposure, and patients were categorized as nonusers, selective estrogen receptor modulator users, aromatase inhibitor users, and both users. Time‐dependent Cox regression models were used to estimate hazard ratios (HRs) and 95% CIs. Age at diagnosis, socioeconomic status, histological type, other treatments, and comorbidities were adjusted in the model. Compared with nonusers, selective estrogen receptor modulator users were associated with higher risks of stroke (HR, 1.20 [95% CI, 1.04–1.40]) and venous thromboembolism (HR, 1.47 [95% CI, 1.13–1.90]), whereas aromatase inhibitor users were associated with a higher risk of coronary heart disease (HR, 1.22 [95% CI, 1.06–1.41]). The risk of type 2 diabetes was associated with selective estrogen receptor modulator users (HR, 1.13 [95% CI, 1.05–1.21]), aromatase inhibitor users (HR, 1.14 [95% CI, 1.05–1.23]), and both users (HR, 1.24 [95% CI, 1.10–1.39]). In particular, the risk of a composite of cardiovascular diseases was higher in younger or premenopausal patients. CONCLUSIONS: In breast cancer survivors in Korea, endocrine therapy is associated with a higher risk of cardiovascular diseases and type 2 diabetes. Monitoring of cancer comorbidities after endocrine therapy is needed in younger and older patients. John Wiley and Sons Inc. 2022-10-17 /pmc/articles/PMC9673673/ /pubmed/36250658 http://dx.doi.org/10.1161/JAHA.122.026743 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Kim, Ji‐Eun Choi, Jaesung Park, JooYong Han, Wonshik Kang, Daehee Choi, Ji‐Yeob Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea |
title | Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea |
title_full | Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea |
title_fullStr | Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea |
title_full_unstemmed | Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea |
title_short | Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea |
title_sort | effects of endocrine therapy on cardiovascular diseases and type 2 diabetes among breast cancer survivors: the national health insurance service database of korea |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673673/ https://www.ncbi.nlm.nih.gov/pubmed/36250658 http://dx.doi.org/10.1161/JAHA.122.026743 |
work_keys_str_mv | AT kimjieun effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea AT choijaesung effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea AT parkjooyong effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea AT hanwonshik effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea AT kangdaehee effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea AT choijiyeob effectsofendocrinetherapyoncardiovasculardiseasesandtype2diabetesamongbreastcancersurvivorsthenationalhealthinsuranceservicedatabaseofkorea |